Literature DB >> 18473793

STAT 3 as a target for cancer drug discovery.

Luca Costantino1, Daniela Barlocco.   

Abstract

Stat-3 (Signal Transduction and Activator of Transcription) is a member of the Stat family of latent, cytosolic transcription factors that directly relate signals from the plasma membrane to the nucleus. This protein is constitutively activated by aberrant upstream tyrosine kinase activities in a broad spectrum of human tumors, and it has been identified as a promising target for cancer drug discovery. This review deals with the recent developments of peptides and peptidomimetics or even non-peptidic small molecules, able to bind to the SH2 domain of Stat-3, thus blocking its functions. Moreover, several compounds able to alter the Stat-3 pathway by inhibition of kinases upstream to Stat-3, or even with unknown targets, were reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473793     DOI: 10.2174/092986708783955464

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  36 in total

1.  Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production.

Authors:  Peter M Abadir; Jeremy D Walston; Robert M Carey; Helmy M Siragy
Journal:  J Interferon Cytokine Res       Date:  2011-02-02       Impact factor: 2.607

2.  The frail renin-angiotensin system.

Authors:  Peter M Abadir
Journal:  Clin Geriatr Med       Date:  2011-02       Impact factor: 3.076

Review 3.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

4.  Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).

Authors:  Huameng Li; Aiguo Liu; Zhenjiang Zhao; Yufang Xu; Jiayuh Lin; David Jou; Chenglong Li
Journal:  J Med Chem       Date:  2011-07-08       Impact factor: 7.446

5.  STAT1 activation regulates proliferation and differentiation of renal progenitors.

Authors:  Honghe Wang; Yili Yang; Nirmala Sharma; Nadya I Tarasova; Olga A Timofeeva; Robin T Winkler-Pickett; Shunsuke Tanigawa; Alan O Perantoni
Journal:  Cell Signal       Date:  2010-07-17       Impact factor: 4.315

6.  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Fengqin Gao; Zhen Lu; Zhiyong Ren; Rajagopal Ramesh; J Sanderson Birtwistle; Kumaralal K Kaluarachchi; Xiaomin Chen; Robert C Bast; Warren S Liao; John S McMurray
Journal:  J Med Chem       Date:  2011-04-26       Impact factor: 7.446

7.  Celastrol suppresses the proliferation of lung adenocarcinoma cells by regulating microRNA-24 and microRNA-181b.

Authors:  Yun-Fei Yan; Han-Han Zhang; Qing Lv; Yue-Mei Liu; You-Jie Li; Bao-Sheng Li; Ping-Yu Wang; Wen-Jing Shang; Zhen Yue; Shu-Yang Xie
Journal:  Oncol Lett       Date:  2017-12-12       Impact factor: 2.967

Review 8.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

9.  Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence.

Authors:  Frederique Caillot; Celine Derambure; Paulette Bioulac-Sage; Arnaud Francois; Michel Scotte; Odile Goria; Martine Hiron; Maryvonne Daveau; Jean Philippe Salier
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

10.  A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Authors:  Edmond J Auzenne; Jim Klostergaard; Pijus K Mandal; Warren S Liao; Zhen Lu; Fengqin Gao; Robert C Bast; Fredika M Robertson; John S McMurray
Journal:  J Exp Ther Oncol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.